Valeo Pharma Receives Hesperco(TM) Natural Product License Approval From Health Canada
(firmenpresse) - - HespercoTM capsules for immune system support to be commercially available by end of September 2020
- HespercoTM pre-sales now available at online store
MONTREAL, QUEBEC , September 3, 2020 - Valeo Pharma Inc. (CSE:VPH, FSE:VP2)
(Valeo or the Company), a Canadian specialty pharmaceutical company, announced today that it has received a Natural Product Licence approval from Health Canada authorizing the sale of its bioflavonoid formulation, HespercoTM, in Canada. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
With the receipt of Health Canadas approval, we are now proceeding with the commercial launch of HespercoTM capsules and are anticipating product availability by end of September 2020, said Steve Saviuk, Valeos President and CEO, HespercoTM capsules will be available in major health care retailers across the country as well as through our dedicated website, www.hesperco.com, which is currently accepting pre-launch orders.
Valeo entered into a collaboration and licensing agreement with Ingenew Pharma Inc. (Ingenew), www.ingenewpharma.com, in April 2020 for the development, manufacture and commercialization of HespercoTM. Ingenew is responsible for providing clinical and scientific data to support the market positioning, commercial and communication campaigns for HespercoTM.
About HespercoTM
https://www.irw-press.at/prcom/images/messages/2020/53265/Hesperco HC approval 09-03-2020 EV Final versionPRcom.001.jpeg
HespercoTM capsules is Valeos unique hesperidin formulation and will be available in bottles of 60 capsules. Hesperidin is a bioflavonoid with powerful antioxidant properties that help support the immune system.
About Valeo Pharma
Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeos objectives, strategies and businesses that involve risks and uncertainties. These statements are forward-looking because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
For more information: Valeo Pharma
Steve Saviuk
President and CEO
514 693-8830
saviuk(at)valeopharma.com
Or
Frederic Dumais
Director Communications and Investor Relations
514-782-8803
dumais(at)valeopharma.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Auryn Accelerates Purchase of Sombrero Concessions from Alturas
Datum: 03.09.2020 - 07:06 Uhr
Sprache: Deutsch
News-ID 1560521
Anzahl Zeichen: 10048
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Valeo Pharma Receives Hesperco(TM) Natural Product License Approval From Health Canada
"
steht unter der journalistisch-redaktionellen Verantwortung von
Valeo Pharma Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
